Hyaluronic acid modified liposomes for targeted delivery of doxorubicin and paclitaxel to CD44 overexpressing tumor cells with improved dual-drugs synergistic effect
Authors:
- Meijia SongMSMeijia Song
- Yan LiangYLYan Liang
- Keke LiKLKeke Li
- Jing ZhangJZJing Zhang
- Nan ZhangNZNan Zhang
- Baocheng TianBTBaocheng Tian
- Jingtian HanJHJingtian Han
- 1 October 2019
- journal article
- research article
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 53
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Shandong Province
- National Natural Science Foundation of China
This publication has 50 references indexed in Scilit:
- Hyaluronic acid-bearing lipoplexes: Physico-chemical characterization and in vitro targeting of the CD44 receptorJournal of Controlled Release, 2012
- DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial DrugsChemistry & Biology, 2010
- Nanostructured hyaluronic acid-based materials for active delivery to cancerExpert Opinion on Drug Delivery, 2010
- Combination therapy: Opportunities and challenges for polymer–drug conjugates as anticancer nanomedicinesAdvanced Drug Delivery Reviews, 2009
- Lipoplexes Targeting the CD44 Hyaluronic Acid Receptor for Efficient Transfection of Breast Cancer CellsMolecular Pharmaceutics, 2009
- Targeted delivery of doxorubicin using stealth liposomes modified with transferrinInternational Journal of Pharmaceutics, 2009
- Extracellularly Activated Nanocarriers: A New Paradigm of Tumor Targeted Drug DeliveryMolecular Pharmaceutics, 2009
- Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination StudiesPharmacological Reviews, 2006
- In vitro and in vivo evaluation of actively targetable nanoparticles for paclitaxel deliveryInternational Journal of Pharmaceutics, 2005
- Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx®) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology GroupAnnals of Oncology, 2002